Skip to content
10-K

Annual Report

PDL BioPharma, Inc.

0000882104-21-000035

← back to feed
Filed
Mar 29, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Jan 6, 2021 114.52M sh
Long Term Debt FY 2020 · Dec 31, 2020 $405K
Cash And Equivalents FY 2020 · Dec 31, 2020 $126.84M
Cash And Equivalents restated FY 2020 · Dec 31, 2019 $168.98M
Shares Diluted FY 2020 · Aug 31, 2020 118M sh
Shares Diluted FY 2020 · Dec 31, 2019 118.63M sh
Shares Diluted FY 2020 · Dec 31, 2018 145.67M sh
Stock Repurchased FY 2020 · Aug 31, 2020 $39.37M
Stock Repurchased FY 2020 · Dec 31, 2019 $86.9M
Stock Repurchased FY 2020 · Dec 31, 2018 $49.11M
Capex FY 2020 · Aug 31, 2020 $221K
Capex FY 2020 · Dec 31, 2019 $763K
Capex restated FY 2020 · Dec 31, 2018 $1.12M
Eps Diluted FY 2020 · Aug 31, 2020 $0.04
Eps Diluted FY 2020 · Aug 31, 2020 −$0.66
Eps Diluted FY 2020 · Jun 30, 2020 −$0.43
Eps Diluted FY 2020 · Mar 31, 2020 −$0.26
Eps Diluted FY 2020 · Dec 31, 2019 −$0.48
Eps Diluted FY 2020 · Dec 31, 2019 −$0.59
Eps Diluted FY 2020 · Sep 30, 2019 −$0.16
Eps Diluted FY 2020 · Jun 30, 2019 −$0.04
Eps Diluted FY 2020 · Mar 31, 2019 $0.05
Eps Diluted FY 2020 · Dec 31, 2018 −$0.47
Eps Basic FY 2020 · Aug 31, 2020 $0.04
Eps Basic FY 2020 · Aug 31, 2020 −$0.66
Eps Basic FY 2020 · Jun 30, 2020 −$0.43
Eps Basic FY 2020 · Mar 31, 2020 −$0.26
Eps Basic FY 2020 · Dec 31, 2019 −$0.48
Eps Basic FY 2020 · Dec 31, 2019 −$0.59
Eps Basic FY 2020 · Sep 30, 2019 −$0.16
Eps Basic FY 2020 · Jun 30, 2019 −$0.04
Eps Basic FY 2020 · Mar 31, 2019 $0.05
Eps Basic FY 2020 · Dec 31, 2018 −$0.47
Sga Expense FY 2020 · Aug 31, 2020 $29.7M
Sga Expense restated FY 2020 · Dec 31, 2019 $38.33M
Sga Expense restated FY 2020 · Dec 31, 2018 $33.7M
Rd Expense FY 2020 · Aug 31, 2020 $4.37M
Rd Expense restated FY 2020 · Dec 31, 2019 $7.35M
Rd Expense restated FY 2020 · Dec 31, 2018 $2.76M
Net Income FY 2020 · Aug 31, 2020 $4.4M
Net Income FY 2020 · Aug 31, 2020 −$77.3M
Net Income FY 2020 · Jun 30, 2020 −$49.97M
Net Income FY 2020 · Mar 31, 2020 −$31.72M
Net Income FY 2020 · Dec 31, 2019 −$54.89M
Net Income FY 2020 · Dec 31, 2019 −$70.41M
Net Income FY 2020 · Sep 30, 2019 −$17.78M
Net Income FY 2020 · Jun 30, 2019 −$4.42M
Net Income FY 2020 · Mar 31, 2019 $6.68M
Net Income FY 2020 · Dec 31, 2018 −$68.86M
Operating Income FY 2020 · Aug 31, 2020 −$54.25M
Operating Income restated FY 2020 · Dec 31, 2019 −$51.12M
Operating Income restated FY 2020 · Dec 31, 2018 −$34.19M
Cost Of Revenue FY 2020 · Aug 31, 2020 $6.63M
Cost Of Revenue restated FY 2020 · Dec 31, 2019 $17.28M
Cost Of Revenue restated FY 2020 · Dec 31, 2018 $13.56M
Revenue FY 2020 · Aug 31, 2020 $13.07M
Revenue FY 2020 · Dec 31, 2019 $30.71M
Revenue FY 2020 · Dec 31, 2018 $32.03M
Stock Issued FY 2020 · Dec 31, 2019 13.38M sh
Stockholders Equity FY 2020 · Dec 31, 2019 $593.2M
Current Liabilities FY 2020 · Dec 31, 2019 $45.69M
Total Liabilities restated FY 2020 · Dec 31, 2019 $123.93M
Current Assets FY 2020 · Dec 31, 2019 $313.9M
Total Assets restated FY 2020 · Dec 31, 2019 $717.21M